Clinical Trials Logo

Myelodysplastic Syndromes (MDS) clinical trials

View clinical trials related to Myelodysplastic Syndromes (MDS).

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04326764 Terminated - Clinical trials for Myelodysplastic Syndromes (MDS)

Panobinostat Maintenance After HSCT fo High-risk AML and MDS

Start date: July 24, 2018
Phase: Phase 3
Study type: Interventional

Aim of this prospective randomized trial is to compare maintenance treatment with panobinostat interspersed with donor lymphocyte infusions (DLI) versus the standard approach of pre-emptive DLI alone in patients with poor-risk AML/MDS having favorably received an allogeneic HSCT followed by engraftment, donor chimerism and hematopoietic reconstitution.

NCT ID: NCT03593915 Terminated - Clinical trials for Myelodysplastic Syndromes (MDS)

A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS

Start date: August 29, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

Alvocidib, a cyclin-dependent kinase 9 (CDK 9) inhibitor, in time-sequential therapy demonstrated significant clinical activity in secondary AML patients with prior MDS. Patients with IPSS-R intermediate and above MDS have an increased risk of developing AML and may be treated with the same chemotherapy regimens used in patients with AML. Eight Phase I or II clinical trials have been completed in patients with AML, totaling more than 400 patients with both relapsed/refractory or newly diagnosed AML. Preclinical studies have demonstrated that decitabine exposure increased the expression of NOXA, which is a specific antagonist of the survival factor MCL 1. Pharmacologic downregulation of MCL-1 via CDK 9 inhibition, as well as upregulation of the MCL-1 antagonist, NOXA, following decitabine exposure may result in enhanced antileukemic activity in MCL-1-dependent malignancies.

NCT ID: NCT01442714 Terminated - Leukemia Clinical Trials

Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS

Start date: August 2011
Phase: Phase 2
Study type: Interventional

The purpose of the trial is to study how the elderly patients who have previously undergone treatment for acute myeloid leukemia and high-rRisk myelodysplastic syndromes, respond to a combined treatment with azacitidine and lenalidomide.

NCT ID: NCT00594230 Terminated - Clinical trials for Myelodysplastic Syndromes (MDS)

LBH589 in Refractory Myelodysplastic Syndromes (MDS)

Start date: January 2008
Phase: Phase 2
Study type: Interventional

This will be a single arm Phase II study.